anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an aerosol preparation for nasal cavity application, having durable activity, effective at a small amount of application and free from side effects, by suspending oxaprozin powder in liquefied propellant gas. CONSTITUTION:Oxaprozin powder having particle diameter of 1-50mum preferably 5-25mum is added to a liquefied propellant gas such as liquefied petroleum gas or chlorofluorocarbon (e.g. flon 12 or flon 22) which are conventional propellant gases for medical aerosol agent. The amount of the powder is 0.5-10wt.% based on the whole composition. The particles are suspended in the liquefied propellant gas by mixing the propellant gas with a liquid produced by dissolving (A) a nonionic liquid surfactant (e.g. higher fatty acid sorbitan ester such as Span 80 or Span 83) having an HLB of <=10 sand giving low irritancy to nasal mucosa in an amount of 0.1-1wt.% (based on the whole composition) in (B) a solvent (e.g. flon 11) compatible with the liquefied propellant gas.
Sham cryoneurolysis of the intercostal nerve of each fractured rib along with one cephalad and one caudad will be targeted: for each nerve the cryoneurolysis device will be triggered using 3 cycles of 2-minute nitrous oxide activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[1st 4 participants\] 3 minutes \[remaining participants; change based on new laboratory data\] of argon and 30 seconds of helium (Varian). However, for the sham comparator, the gas will NOT be deployed to the tip, there there will NOT be a drop in temperature, and NO cryoneurolysis will occur.
Administration of SUNLENCA may result in local injection site reactions (ISRs). If clinically significant ISRs occur, evaluate and institute appropriate therapy and follow-up.

Manifestations of ISRs may include swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass. Nodules and indurations at the injection site may take longer to resolve than other ISRs. In clinical studies, after a median follow-up of 553 days, 30% of nodules and 13% of indurations (in 10% and 1% of subjects, respectively) associated with the first injections of SUNLENCA had not fully resolved. Measurements and qualitative assessments of ISRs were not routinely reported. Where described, the majority of the injection site nodules and indurations were palpable but not visible, and had a maximum size of approximately 1 to 4 cm [see Adverse Reactions (6.1)].

The mechanism driving the persistence of injection site nodules and indurations in some patients is not fully understood, but based on available data, they may be related to the presence of the subcutaneous drug depot. In some patients who had a skin biopsy performed of an injection site nodule or induration, dermatopathology revealed foreign body inflammation or granulomatous response.
The acupuncture points were bilaterally punctured by a stainless steel acupuncture needle (length 30mm x diameter 0.25) (Dongbang, Boryeong, Chungnam- Korea). We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the "De Qi" perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher.
The present invention discloses a multiple-flavor freeze drying gastrodiae tuber food containing propolis tincture, which belongs to the technical field of health care and leisure foods, particularly to the field of multiple-flavor freeze drying gastrodia tuber foods containing propolis tincture. The gastrodia tuber food is made by mixing gastrodia tuber and propolis tincture according to the proportion of 10000: 650 to 10000: 400. The propolis tincture enters the gastrodia tuber, spice powder in various flavors is mixed with the gastrodia tuber containing propolis tincture, and the gastrodia tuber is dried into the spongy gastrodia tuber food having no drying shrinkage and good condensing performance by a vacuum freeze drier after the gastrodia tuber is bloated for half day to one and a half day. The present invention has a novel and unique technological scheme, combines the gastrodia tuber and propolis which have better complemental efficacy and functions and provides a health food with excellent efficacy. The food solves the problem of the bad flavor of propolis, uses fresh gastrodia tuber to avoid artificial pollution during processing and overcomes the defect that the gastrodia tuber can not be eaten easily after processing. The food preserves the bioactivity of the gastrodia tuber and the propolis tincture.
Systemic exposure of adapalene following a topical application of DIFFERIN Lotion was studied in two pharmacokinetic (PK) clinical trials. The first trial was conducted in 14 adult subjects 18 to 29 years of age with severe acne and the second trial was conducted in 13 adolescent subjects 12 to 17 years of age with moderate to severe acne.

In each trial, subjects were treated with 2 g of DIFFERIN Lotion applied once daily to approximately 1000 cm² of acne involved skin for 28 days (adolescent subjects) or 30 days (adult subjects). Serial plasma samples were collected at 24 or 72 hours following application on days 1, 15 and 28/30.

Daily topical application of DIFFERIN Lotion resulted in low systemic exposure to adapalene in the two populations (adult and adolescent subjects). In the adult population, all plasma concentrations in 12 out of 14 subjects were below the limit of quantification (LOQ=0.1 ng/mL). One subject had one sample above LOQ at day 30 and the other subject had four plasma samples above LOQ on both days 1 and 15, which ranged from 0.102 and 0.131 ng/mL.

In the adolescent population, plasma concentrations were quantifiable (>0.1 ng/mL) in five subjects. On Day 28, the mean C maxwas 0.128 ± 0.049 ng/mL (range: <0.100 to 0.244 ng/mL) and the mean of AUC 0-24hrwas 3.07 ± 1.21 ng.hr/mL (range: 1.86 to 4.93 ng.hr/mL). Adapalene plasma concentrations in all subjects were below the limit of quantification (<0.1 ng/mL) 48 hours after the last application on Day 28.
The application provides novel neuroactive fragments of human amyloid pre cursor protein (APP). The fragments include sequence from the A.beta. region of APP but also extend upstream. The fragments are soluble in aqueous solut ion most bands are about 10 kDa and above and do not correspond with the exp ected molecular weight of a dimer or trimer. The fragments and sub fragments thereof can be used as immunogens in methods of immunotherapy to treat Alzh eimer's and other amyloidogenic diseases characterized by deposits of A.beta . in the brain. Antibodies to the part of the fragment upstream from APP or the interface between A.beta. and the upstream sequence can also be used in such therapeutic method. The fragments are also useful as markers, which can be detected for diagnosis or prognosis of disease or for screening agents.< /SDOAB>
FIELD: medicine. SUBSTANCE: needleless syringe has nozzle, split barrier positioned at its input end, forcing facility and therapeutic facility arranged between nozzle and forcing facility. Nozzle is of extended tubular form. Breakable membrane which closes channel through nozzle initially serves as split barrier. Therapeutic facility in form of particles is positioned near membrane. Forcing facility contains gas designed to break membrane and to produce ultrasonic flux through nozzle for transfer of therapeutic facility in form of particles and for injection of these particles through patient's skin. Method includes introduction of therapeutic facility particles at definite speed. Size of particles is from 0.1 to 250 mcm, and their density is from 0.1 to 25 g/cu.cm. EFFECT: provision for noninvasive system of drug injection into intact skin. 70 cl, 1 ex, 8 dwg
College students have high rates of post-traumatic stress disorder (PTSD) symptoms as well as high rates of sexual assault. What is less clear, however, is whether different sexual assault types (e.g. coercive, physically forced, and incapacitation) are associated with greater PTSD symptoms. Moreover, understanding early familial and mental health histories of college students is important for explaining PTSD symptoms. As such, we use a social stress framework to examine the relationships between early familial risk (i.e. child abuse, perceived maternal rejection), borderline personality (BP) symptoms, and three sexual assault types with PTSD symptoms among college students. A total of 783 undergraduate students (65.4% female) completed paper and pencil surveys in fall 2019 and spring 2020 at a large public university. Results revealed that females were more likely to experience child sexual abuse and all three forms of sexual assault, while males experienced higher rates of child physical abuse. OLS regression results showed positive associations between child sexual abuse, perceived maternal rejection, BP symptoms and all three types of sexual assault with PTSD symptoms. Females also experienced more PTSD symptoms compared to males. Findings have implications for targeted interventions to improve mental health outcomes.
Selective sepn. of virus from non-virus protein in which (a) ammonium sulphate is added to an aqs. biological fluid contg. virus and non-virus protein to a concn. which is sufficient to ppte. the non-virus protein but not the virus; (b) sepg. the pptd. protein; (c) treating the filtrate or supernatant with a water-insol. polymeric polyelectrolyte, this polymer being polycationic or polyampholytic and contg. dialkylaminoalkylimide or alkylaminoalkylimino gps., at a pH 7 but above that at which the virus is perceptibly unstable in order to adsorb the virus on the polyelectrolyte, and (d) sepg. the polyelectrolyte and adsorbed virus from the soln. Vaccines made from viruses purified in this way are less likely to give rise to anaphyloxis. Esp. useful for isolating influenza virus from allantoic fluid. Pref. adsorption pH = 4.5-5.5.
Selenium Injection can be toxic if given in excessive amounts. Supplementation of TPN solution with selenium should be immediately discontinued if toxicity symptoms are observed. Frequent determination of plasma selenium levels during TPN support and close medical supervision is recommended.

Selenium Injection is a hypotonic solution and should be administered in admixtures only.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
The invention discloses Ziziphora tenuior Linn. water extract and its use in preparation of drugs having effects of sedation and hypnosis, immunity improvement, and spleen and stomach regulation. A preparation method of the Ziziphora tenuior Linn. water extract comprises the following steps of 1, weighing dried whole herb of Ziziphora tenuior Linn. (sieved by a sieve of 40 meshes), adding distilled water into the dried whole herb of Ziziphora tenuior Linn., wherein the weight of the distilled water is 10 times that of the dried whole herb of Ziziphora tenuior Linn., 2, carrying out reflux extraction for 1 hours or normal temperature immersion for 18 to 24 hours (overnight) or immersion at a temperature of 37 DEG C for 15 to 20 hours, 3, carrying out extraction twice, 4, carrying out filtration, washing filter residue, and merging the filtrate in a bottle, 5, concentrating the merged filtrate, and 6, metering the volume of the concentrated filtrate to 100mL by distilled water so that a Ziziphora tenuior Linn. water extract sample solution having a concentration of 0.1g crude drug/mL is obtained. An animal experiment proves that the Ziziphora tenuior Linn. water extract has effects of sedation and hypnosis, immunity improvement, spleen and stomach regulation, and digestion promotion, and has a certain concentration dependence. An animal acute toxicity experiment proves the Ziziphora tenuior Linn. water extract is safe in clinical application and nontoxic.
OBJECTIVES: Efficient and timely transportation of clinical samples is pivotal to ensure accurate diagnoses and effective patient care. During the transportation process, preservation of sample integrity is crucial to avoid pre-analytical aberrations on laboratory results. Here, we present a comparative analysis between a two-step Tempus600 hub solution single-tube and a one-step, container-based pneumatic transport system (PTS) from Airco, for the in-house transportation of blood samples.
METHODS: Ten blood samples from healthy volunteers were split in 10 mL collection tubes filled at full or half capacity for transportation with the two PTS (about 250 m). To compare the impact of transportation, markers of hemolysis such as lactate dehydrogenase (LDH), potassium (K+), and the hemolysis index (HI), were determined. Additionally, differences in HI in routine samples and repeated transportation was investigated. To assess and compare the mechanistic impact profiles, we recorded the acceleration profiles of the two PTS using a shock data logger.
RESULTS: Transportation using the Tempus600 hub solution resulted in 49 and 46 % higher HI with samples filled to total or half capacity, respectively. Routine samples transported with the Tempus600 hub solution showed a higher median HI by 23 and 33 %. Additionally, shock logger analysis showed an elevated amount of shocks (6.5 fold) and shock intensities (1.8 fold).
CONCLUSIONS: The Tempus600 hub solution caused an increased number of unreportable LDH or K+ results based on the hemolysis index. However, it was only statistically significant for LDH (p<0.01 and p<0.08) - while the comparisons for K+ were not statistically significant (p<0.28 and p<0.56).
A robot system that includes a remote station and a robot face. The robot face includes a camera that is coupled to a monitor of the remote station and a monitor that is coupled to a camera of the remote station. The robot face and remote station also have speakers and microphones that are coupled together. The robot face may be coupled to a boom. The boom can extend from the ceiling of a medical facility. Alternatively, the robot face may be attached to a medical table with an attachment mechanism. The robot face and remote station allows medical personnel to provide medical consultation through the system.
The intervention for the CBT-I + UC group will involve five weekly 50-minute individual, face-to-face sessions of CBT-I. The treatment components aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia whilst considering the clinical context of ADHD and include: psycho-education about ADHD, sleep, circadian rhythm and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
The invention relates to a drug for treating alopecia areata. The drug for treating the alopecia areata is prepared from, by weight, 8 parts of radix bupleuri, 8 parts of radix scrophulariae, 6 parts of red paeony roots, 6 parts of fructus amomi, 6 parts of amomum tsao-ko, 6 parts of spora lygodii, 6 parts of semen plantaginis, 3 parts of radix angelica sinensis, 3 parts of white atractylodes rhizomes, 4 parts of dogwood, 4 parts of prepared rehmannia roots and 3 parts of honey-fried licorice roots. An inventor believes that the alopecia areata is related to phlegm and dampness stagnation and dysfunctions of heart, spleen, liver and kidney. During application, the radix bupleuri harmonizes the exterior and interior, sooths the liver and raises yang; the radix scrophulariae cools blood, nourishes yin and relieves internal toxicity; the red paeony roots cools blood and promotes blood circulation; the fructus amomi warms the spleen and resolves dampness; the amomum tsao-ko eliminates dampness and warms the middle warmer; the spora lygodii and the semen plantaginis dredges stranguria and excretes dampness; the radix angelica sinensis performs hematogenesis and nourishes heart; the white atractylodes rhizomes strengthens spleen and stimulates appetite; the dogwood supplements the liver and kidney; the prepared rehmannia roots enriches yin and nourishes kidney; the honey-fried licorice roots moderates the properties of the herbs. The herbs are combined for usage and jointly have the effects of reducing phlegm, clearing damp and making the five internal organs harmonious. The purpose of treating the alopecia areata is achieved. Clinical experiments show that the drug can safely and effectively treat the alopecia areata.
PURPOSE:To obtain the subject modifier, having parts with affinity for specific hemocytic cells and low-adhesive parts to water-insoluble solid substances in the molecule and suitably used for purely separating, purifying and concentrating the hemocytic cells with minimized functional damage. CONSTITUTION:A hemocytic cell modifier, selected from saccharide chains, glycoproteins, immunoglobulins, hydrophobic organic synthetic substances, peptides, amino acids, etc., and having parts with affinity for specific hemocytic cells and low-adhesive parts (e.g. hydroxyl group or carbonyl group) to water- insoluble solid substances. The aforementioned modifier is brought into contact with a solution which contains plural hemocytic cells and is to be treated to modify the objective specific hemocytic cells. The resultant solution to be treated is subsequently brought into contact with the water-insoluble solid substances to adhere other existing hemocytic cells to the aforementioned solid substances and recover only the specific cells. The above-mentioned modifier is preferably prepared by binding the parts exhibiting low adhesion to the water-insoluble solid substances, such as polyhydric alcohol or carbonic acid derivative, to a compound having affinity for the specific hemocytic cells.
The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
The invention relates to decoction for treating renal calculus and urethral calculus, which belongs to a traditional Chinese medicine for treating the renal calculus and the urethral calculus. The decoction comprises the following raw materials of medicines: yanchuncao and chicken's gizzard-membrane. The decoction is prepared by adding water into the yanchuncao and the chicken's gizzard-membrane and decocting for 20 minutes. The decoction has good effect and quick acting for treating the renal calculus and the urethral calculus and can achieve the aims of dissolving calculus, promoting blood circulation, dissolving stasis, promoting urination and removing calculus. The medicine is a purely natural Chinese herbal medicine product, has no toxic or side effect to a human body, is suitable for treating the renal calculus and the urethral calculus, has optimal curative effect and can cure the renal calculus and the urethral calculus by being taken for 2-4 times. The statistics of more than 200 cases of trial shows that the cure after-effect of a patient is good, the total effective rate reaches more than 90%, the cure rate reaches more than 85%, and the invention is suitable for the treatment of the renal calculus and the urethral calculus.
Patients receive minnelide PO QD on days 1-21 and osimertinib PO QD on days 1-28. Cycles repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
The main objective of this study is to determine if the drug Modafinil is effective in the treatment of fatigue in patients with post-polio syndrome (PPS). PPS is a motor neuron disease experience by more than 400,000 Americans, characterized by new weakness and intense fatigue. The cause of fatigue, the most common and disabiling symptom in these patients, is unknown and there is no effective treatment. In the present study, selected PPS patients will be randomized to receive two different doses of Modafinil or placebo. After six weeks, the patients will enter a two-week wash out period, and then will be crossed over to the other arm. The sample size has been powered to reflect a significant difference in the scales of fatigue. Secondary exploratory studies will include investigation of sleep patterns as a cause contributing to fatigue and a search for upregulation of fatigue-associated cytokines in the patient's serum and CSF.
Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times.
PURPOSE:To provide an antieumycetic agent containing an isoxazole derivative as an active component, exhibiting fungicidal effect to pathogenic eumycetes, and useful for medical or animal treatment use. CONSTITUTION:The objective agent contains the compound of formula I [R<1> is H, alkyl, (substituted) phenyl, thienyl, or furyl; R<2> is H, alkyl, alkoxy or halogen; R<3> is H, alkyl, alkenyl, etc.; X is Cl, Br or I; excluding the case that R<2> and R<3> are H and R<1> is 5-substituted phenyl, thienyl or furyl] as an active component. The compound of formula  I is an isoxazole derivative having a haloacetamide group at 3, 4 or 5 site and includes novel compounds. A compound of formula I wherein X is I can be prepared e.g. by reacting the compound of formula IIwith a monohalogenoacetyl halide in the presence of pyridine, and reacting the resultant compound of formula III (X' is Br or Cl) with NaI. The compound of formula I exhibits strong fungicidal effect against the eumycetes of man and animal.